The cell line is not validated yet.
BIHi329-A
General
iPSC Line |
|
| hPSCreg name | BIHi329-A |
| Cite as: | BIHi329-A |
| iPSC line type | Human induced pluripotent stem cell (hiPSC) |
| Similar iPSC lines | No similar lines found. |
| Last update | 18th August 2026 |
| User feedback | |
Provider |
|
| Generator |
Berlin Institute of Health (BIH)
Contact:
Berlin Institute of Health (BIH) |
| Owner | Berlin Institute of Health (BIH) |
| Distributors | |
| Derivation country | Germany |
General iPSC Information |
|
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 30-34 |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Has the donor agreed to be re-contacted? | Unknown |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| * Does consent pertain to a specific research project? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Ethical commission - CVK Charité |
| Approval number | EA2/069/21 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
iPSC Derivation
General |
|
| Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
| Age of donor (at collection) | 30-34 |
| Collected in | 2026 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | LNP-RNA provided by uBrigene |
| Is reprogramming vector detectable? |
Unknown |
| Notes on reprogramming vector detection | Detection of vector is not expected |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
iPSC Culture Conditions
| Surface coating | Matrigel/Geltrex | ||||||
| Feeder cells |
No |
||||||
| Passage method |
Enzyme-free cell dissociation
EDTA
|
||||||
| O2 Concentration | 5 % | ||||||
| CO2 Concentration | 5 % | ||||||
| Medium |
Essential 8™
Supplements
|
||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this iPSC line? | Unknown |
||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this iPSC line? | Unknown |
||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this iPSC line? | Unknown |
iPSC Characterisation
Analysis of undifferentiated iPSCs
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
|
|||
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| SSEA-4 |
Yes |
|
|
Differentiation Potency
In vitro directed differentiation
In vitro directed differentiation
In vitro directed differentiation
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping
Karyotyping (iPSC Line) |
|
| Has the iPSC line karyotype been analysed? |
Yes
|
Other Genotyping (iPSC Line) |
|
Login to share your feedback, experiences or results with the research community.